Patients' characteristics based on response to treatment
| . | CR (n = 5) . | PR (n = 5) . | MR (n = 3) . | NR (n = 12) . | P . |
|---|---|---|---|---|---|
| Sex (F/M) | 5/0 | 3/2 | 1/2 | 7/5 | .2368 |
| Median age, y | 29 | 45 | 52 | 49.5 | .3185 |
| Median baseline platelet count, × 109/L | 11 | 9 | 17 | 13.5 | .4370 |
| Median ITP duration before rituximab treatment, mo | 25 | 19 | 12 | 33.5 | .5167 |
| Prior splenectomy (n = 8) | 1 | 2 | 0 | 5 | .9342 |
| . | CR (n = 5) . | PR (n = 5) . | MR (n = 3) . | NR (n = 12) . | P . |
|---|---|---|---|---|---|
| Sex (F/M) | 5/0 | 3/2 | 1/2 | 7/5 | .2368 |
| Median age, y | 29 | 45 | 52 | 49.5 | .3185 |
| Median baseline platelet count, × 109/L | 11 | 9 | 17 | 13.5 | .4370 |
| Median ITP duration before rituximab treatment, mo | 25 | 19 | 12 | 33.5 | .5167 |
| Prior splenectomy (n = 8) | 1 | 2 | 0 | 5 | .9342 |
CR indicates complete response; PR, partial response; MR, minor response; NR, no response.